2-Hydroxyoleic acid - Lipopharma Therapeutics

Drug Profile

2-Hydroxyoleic acid - Lipopharma Therapeutics

Alternative Names: 2-hydroxy-9-cis octadecenoic - Lipopharma; 2-OHOA - Lipopharma Therapeutics; Minerval

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator University of the Balearic Islands
  • Developer Lipopharma
  • Class Anorectics; Antineoplastics; Oleic acids
  • Mechanism of Action Membrane lipid modulators; Phosphatidylcholine ceramide phosphocholine transferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma; Solid tumours

Most Recent Events

  • 05 Jun 2017 Adverse events data from a phase I/II trial in Solid tumours and Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Sep 2016 Lipopharma completes a phase I/II trial for Glioma and other Solid tumours in Spain and United Kingdom (NCT01792310)
  • 01 Aug 2016 Efficacy and adverse events data from phase I/II trial in Solid tumours and Glioma released by Lipopharma Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top